بررسی اثربخشی درمان سرطان با روش Inhibitor Therapy روی بیماران How Should We Assess Benefit in Patients Receiving Checkpoint Inhibitor Therapy?
- نوع فایل : کتاب
- زبان : انگلیسی
- چاپ و سال / کشور: 2018
توضیحات
رشته های مرتبط پزشکی
گرایش های مرتبط ایمنی شناسی، انکولوژی
مجله انجمن آمریکایی انکولوژی بالینی – American Society of Clinical Oncology
دانشگاه University of California Los Angeles – Jonsson Comprehensive Cancer Center – Los Angeles – CA
گرایش های مرتبط ایمنی شناسی، انکولوژی
مجله انجمن آمریکایی انکولوژی بالینی – American Society of Clinical Oncology
دانشگاه University of California Los Angeles – Jonsson Comprehensive Cancer Center – Los Angeles – CA
Description
In recent years, immunotherapy has revolutionized the treatment of cancer. Immunotherapy has been used for decades (vaccines, interferon, high-dose interleukin 2), but only since the introduction of checkpoint inhibitors has it had a significant impact on the survival of patients with a variety of cancers. Currently, checkpoint inhibitors involving two specific targets are approved by the US Food and Drug Administration: cytotoxic T-cell lymphocyte-4–blocking antibodies (ipilimumab, approved by the US Food and Drug Administration for patients with melanoma) and programmed cell death protein 1/programmed death ligand 1–blocking antibodies (atezolizumab, avelumab, durvalumab, nivolumab, and pembrolizumab for patients with melanoma, renal cell carcinoma, non–small-cell lung cancer, head and neck cancer, bladder cancer, Merkel cell carcinoma, Hodgkin lymphoma, and others). As clinical trials with checkpoint inhibitors were ongoing, it was noted that occasionally atypical patterns of responses (a transient increase in the size of lesions or even appearance of new lesions) were seen, and therefore the most commonly used response criteria, namely Response Evaluation Criteria in Solid Tumors (RECIST) v1.1, may not capture all patients who received benefit from these therapies.
